

24 August 2026

Re: Notice to Health Care Providers and Entities

As you may be aware, Veloxis recently entered into a civil, criminal and administrative settlement with the United States and individual states in connection with the promotion and sale of Envarsus XR, our kidney transplant immunosuppressant drug. This letter provides you with additional information about the global settlement, explains Veloxis' commitments going forward, and provides you with access to information about those commitments.

In general terms, the Government alleged that Veloxis paid kickbacks to hospital personnel and specialty pharmacies to induce prescriptions and purchases of Envarsus XR. Veloxis has admitted liability and accepted responsibility for this conduct. To resolve a criminal kickback conspiracy charge, Veloxis entered into a three-year deferred prosecution agreement and agreed to pay a criminal penalty of \$10.04 million. In addition, to resolve civil liability under the Federal False Claims Act, Veloxis agreed to pay \$34.45 million for allegedly causing the submission of claims tainted by kickbacks. Veloxis also agreed to pay a civil penalty of \$1.55 million to resolve allegations Veloxis failed, under the Open Payments Program, to report to CMS amounts paid to physicians. Together, Veloxis agreed to pay more than \$46 million in connection with this resolution. More information about this settlement may be found at the following:

<https://www.justice.gov/opa/pr/veloxis-pharmaceuticals-agrees-pay-over-46m-resolve-criminal-and-civil-liability-kickback>.


As part of the global settlement, Veloxis also entered into a five-year corporate integrity agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. The corporate integrity agreement is available at:

<https://oig.hhs.gov/compliance/corporate-integrity-agreements/>. Under this agreement, Veloxis agreed to undertake certain requirements designed to promote compliance with Federal health care

program and FDA requirements. We also agreed to notify healthcare providers about the settlement and inform them that they can report any questionable practices by Veloxis' representatives to Veloxis' Compliance organization or the FDA using the information set out below.

Please call Veloxis at 1-833-214-6429 or visit us at <https://report.syntrio.com/aktx> if you have questions about the settlement referenced above. Please call Veloxis at 1-833-214-6429 or visit us at <https://report.syntrio.com/aktx> to report any instances in which you believe that a Veloxis representative inappropriately promoted a product or engaged in other questionable conduct. Alternatively, you may report any improper conduct associated with prescription drug marketing committed by a Veloxis representative to the FDA's Office of Prescription Drug Promotion at 301-796-1200. You should direct medical questions or concerns about Veloxis products to 1-844-VELOXIS.

Sincerely,



Stacy G. Wheeler
Chief Executive Officer